Drug intelligence / Profile preview

ALY-291

Development stage: Preclinical
Lead developer: Alys Pharmaceuticals
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules
Administration: Transdermal

Overview

ALY-291 is a preclinical-stage small molecule therapeutic being developed by Alys Pharmaceuticals (following its acquisition of Granular Therapeutics) for the treatment of Hidradenitis Suppurativa (HS) and Pyoderma gangrenosum (PG). The drug is formulated using a nanoparticle-loaded microneedle delivery system for transdermal administration. This delivery platform is designed to enhance the local penetration and sustained release of the therapeutic agent within the dermis, targeting the inflammatory pathways associated with chronic skin diseases while minimizing systemic exposure to the active ingredient.

Beyond the preview

Go deeper on ALY-291.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALY-291.

Explore the full profile